MINI FUTURE LONG - ZEALAND PHARMA | Real-time Bid/Ask 08:28:03 2024-05-29 EDT | ||
| 7 EUR / 7.05 EUR | +0.36% |
|
| Current month | -1.13% | ||
| 1 month | +0.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-29 | 6.92 | -1.14% |
| 24-05-28 | 7 | +2.94% |
| 24-05-27 | 6.8 | +5.43% |
| 24-05-24 | 6.45 | -3.87% |
| 24-05-23 | 6.71 | -1.03% |
Delayed Quote Börse Stuttgart
Last update May 29, 2024 at 04:51 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MB1FVD |
| ISIN | DE000MB1FVD9 |
| Date issued | 2022-12-15 |
| Strike | 99.48 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.8 € |
|---|---|
| Lowest since issue | 1.38 € |
| Spread | 0.05 € |
| Spread % | 0.71% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
614.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+27.84%
- Stock Market
- Certificates
- Certificat
